ArticleGigaScience2022
SYNPRED: prediction of drug combination effects in cancer using different synergy metrics and ensemble learning.
Article in GigaScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- A Machine Learning Approach for Predicting Synergism of Mixtures of Compounds in Treating Cancers.International journal of molecular sciences · 2026Article
- CLC-Pred Synergy: Web Application for Predicting Pairwise Drug Combinations with Synergistic Activity Against NCI60 Cancer Cell Lines.International journal of molecular sciences · 2026Article
- Rethinking Nature's Pharmacy: AI Era and Natural Product Drug Discovery.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Exploring Artificial Intelligence's Potential to Enhance Conventional Anticancer Drug Development.Drug development research · 2025Review
- Machine Learning for Multi-Target Drug Discovery: Challenges and Opportunities in Systems Pharmacology.Pharmaceutics · 2025Review
- Optimizing kinase and PARP inhibitor combinations through machine learning and in silico approaches for targeted brain cancer therapy.Molecular diversity · 2025Article
- Interpretable prediction of drug synergy for breast cancer by random forest with features from Boolean modeling of signaling pathways.Scientific reports · 2025Article
- Risk-based evaluation of machine learning-based classification methods used for medical devices.BMC medical informatics and decision making · 2025Article
- The present and future of the Cancer Dependency Map.Nature reviews. Cancer · 2025Review
- DD-PRiSM: a deep learning framework for decomposition and prediction of synergistic drug combinations.Briefings in bioinformatics · 2024Article
- A multi-task graph deep learning model to predict drugs combination of synergy and sensitivity scores.BMC bioinformatics · 2024Article
- A multi-view feature representation for predicting drugs combination synergy based on ensemble and multi-task attention models.Journal of cheminformatics · 2024Article
- piscesCSM: prediction of anticancer synergistic drug combinations.Journal of cheminformatics · 2024Article
- Advancing Drug Safety in Drug Development: Bridging Computational Predictions for Enhanced Toxicity Prediction.Chemical research in toxicology · 2024Review
- PermuteDDS: a permutable feature fusion network for drug-drug synergy prediction.Journal of cheminformatics · 2024Article
- A Deep Neural Network for Predicting Synergistic Drug Combinations on Cancer.Interdisciplinary sciences, computational life sciences · 2024Article
- New Perspective for Using Antimicrobial and Cell-Penetrating Peptides to Increase Efficacy of Antineoplastic 5-FU in Cancer Cells.Journal of functional biomaterials · 2023Article
- DELFOS-drug efficacy leveraging forked and specialized networks-benchmarking scRNA-seq data in multi-omics-based prediction of cancer sensitivity.Bioinformatics (Oxford, England) · 2023Article
- SYNDEEP: a deep learning approach for the prediction of cancer drugs synergy.Scientific reports · 2023Article
- A systematic evaluation of deep learning methods for the prediction of drug synergy in cancer.PLoS computational biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn cancer research, high-throughput screening technologies produce large amounts of multiomics data from different populations and cell types. However, analysis of such data encounters difficulties due to disease heterogeneity, further exacerbated by human biological complexity and genomic variability. The specific profile of cancer as a disease (or, more realistically, a set of diseases) urges the development of approaches that maximize the effect while minimizing the dosage of drugs. Now is the time to redefine the approach to drug discovery, bringing an artificial intelligence (AI)-powered informational view that integrates the relevant scientific fields and explores new territories.
resultsHere, we show SYNPRED, an interdisciplinary approach that leverages specifically designed ensembles of AI algorithms, as well as links omics and biophysical traits to predict anticancer drug synergy. It uses 5 reference models (Bliss, Highest Single Agent, Loewe, Zero Interaction Potency, and Combination Sensitivity Score), which, coupled with AI algorithms, allowed us to attain the ones with the best predictive performance and pinpoint the most appropriate reference model for synergy prediction, often overlooked in similar studies. By using an independent test set, SYNPRED exhibits state-of-the-art performance metrics either in the classification (accuracy, 0.85; precision, 0.91; recall, 0.90; area under the receiver operating characteristic, 0.80; and F1-score, 0.91) or in the regression models, mainly when using the Combination Sensitivity Score synergy reference model (root mean square error, 11.07; mean squared error, 122.61; Pearson, 0.86; mean absolute error, 7.43; Spearman, 0.87). Moreover, data interpretability was achieved by deploying the most current and robust feature importance approaches. A simple web-based application was constructed, allowing easy access by nonexpert researchers.
conclusionsThe performance of SYNPRED rivals that of the existing methods that tackle the same problem, yielding unbiased results trained with one of the most comprehensive datasets available (NCI ALMANAC). The leveraging of different reference models allowed deeper insights into which of them can be more appropriately used for synergy prediction. The Combination Sensitivity Score clearly stood out with improved performance among the full scope of surveyed approaches and synergy reference models. Furthermore, SYNPRED takes a particular focus on data interpretability, which has been in the spotlight lately when using the most advanced AI techniques.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.